Searching for your content...
In-Language News
Contact Us
888-776-0942 from 8 AM - 10 PM ET
A survey of 124 US nephrologists, conducted just last week, identifies acute kidney injury (AKI), diabetic kidney disease (DKD), and polycystic...
The European regulatory authorities tend to be moving in a different direction than U.S. Food and Drug Administration (FDA) regarding novel HIF-PH...
Vitiligo is a disease that causes loss of skin color in patches when cells that produce melanin die or stop functioning.1 Spherix recently surveyed...
Spherix recently surveyed 200 EU-based dermatologists across France, Germany, Italy, Spain, and the UK and followed up with ten qualitative...
With the approvals of GlaxoSmithKline's Benlysta in lupus nephritis (LN) at the end of 2020 and Aurinia's Lupkynis at the beginning of 2021,...
As the chronic kidney disease (CKD) and diabetic kidney disease (DKD) treatment landscapes rapidly evolve, nephrologists are providing important...
On May 20, 2022, the FDA approved Sanofi/Regeneron's Dupixent, the first therapy indicated to treat eosinophilic esophagitis (EoE). In response,...
Spherix Global Insights, a leading market intelligence firm specializing in immunology-based research and insights, recently published several...
According to the latest deep dive report included in Spherix's Launch Dynamix™: Qulipta for Migraine Prevention (US) service, surveyed neurologists...
Three months into the launch of argenx's Vyvgart for generalized myasthenia gravis (gMG) in patients who are anti-acetylcholine receptor antibody...
Fabry disease is an extremely rare genetic condition most prevalent in men and potentially underdiagnosed in women. Nephrologists rank it as one of...
After several years of lackluster reception towards off-label biosimilar, Genentech's Avastin (bevacizumab), ophthalmologists have finally seen the...
Fellows will be the next generation of practitioners. Most academic institutions have closed-door policies for industry, leaving a large gap in...
According to the latest deep dive report published as part of Spherix's Launch Dynamix™: Rinvoq in Ulcerative Colitis (US) service, AbbVie's...
Glomerulonephritis is a major contributor of end-stage renal disease across the globe, with IgA nephropathy (IgAN), also known as Berger's disease,...
Spherix recently surveyed 103 US gastroenterologists and 20 hepatologists, along with conducting eight qualitative interviews (including 2 KOLs and 6 ...
Following an eventful 2021 that included the launch of two new brands—Novartis' Kesimpta and BMS' Zeposia—and generic versions of Biogen's Tecfidera, ...
On April 7, 2022, CMS finalized its NCD for anti-amyloid monoclonal antibodies (mAbs) for the treatment of Alzheimer's disease. Given the importance...
Spherix recently surveyed 102 gastroenterologists and 100 primary care physicians (PCPs), including eight qualitative interviews with...
At the beginning of this year, Spherix Global Insights, a leading market intelligence firm, expanded their coverage of select specialty markets with...
The approval of several renal pipeline products in the European market has granted nephrologists new options through which they can manage their...
The US rheumatoid arthritis (RA) biologic and small molecule market has remained relatively stagnant over the past few years, with little change in...
Spherix Global Insights, a leading market intelligence firm specializing in neurology-based research and insights, has been tracking the multiple...
IgA nephropathy (IgAN) is generally recognized as the most common glomerular nephritis disease globally, impacting many patients and often resulting...
Spherix recently surveyed 76 gastroenterologists and 26 infectious disease (ID) physicians (including 8 qualitative interviews between both...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.